Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLS004
- Development stage
- Preclinical
- Lead developer
- Cellusion
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
CLS004 is a preclinical-stage cell therapy being developed by Cellusion for the treatment of bullous keratopathy and other corneal endothelial diseases. The therapy utilizes Cellusion's proprietary technology to generate corneal endothelial cell substitutes from induced pluripotent stem cells (iPSCs). This approach is designed to provide a scalable and standardized alternative to traditional corneal transplants, which are currently limited by a global shortage of donor tissue. By replacing damaged or depleted endothelial cells, CLS004 aims to restore the cornea's ability to regulate fluid balance, thereby resolving corneal edema and restoring vision.
Beyond the preview
Go deeper on CLS004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLS004.